FAT1 and metastatic neoplasm: Interestingly, our patient had FAT1 and TERT promoter mutations in the metastatic tumor, while they were not observed in the primary tumor FAT1 mutation was observed in 21.7% of the HNSCC samples in The Cancer Genome Atlas (TCGA) database.12